Novo Nordisk Says Ozempic ‘Very Likely’ to Be on 2027 Medicare Negotiation List: Bloomberg

Novo Nordisk (NYSE: NVO), the Danish drugmaker, expects its diabetes drug Ozempic will “very likely” be on the U.S. government’s 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive.

Part of 2022’s Inflation Reduction Act allows Medicare to negotiate prices for prescription drugs that had been particularly expensive for the federal health program which covers millions of Americans aged 65 and older as well as the disabled.

Novo executives have previously said it is too soon to know the impact of the negotiations on Ozempic. Wall Street analysts are also betting on a 2027 list that will include Ozempic.

The company did not immediately respond to a Reuters request for comment.

(Source: ReutersReuters)

Novo Nordisk NYSE: NVO Ozempic

Jennifer Tacker

Jennifer Tacker is a staff writer at ABBO News. She holds a B.A. from the University of Waterloo and a B.Ed from Western University. Jennifer has been active in the stock market and crypto sector for a decade. She specializes in technical analysis and trading strategies.

See Full Bio